NexImmune, Inc. (NEXI)

3,1226 -0,0274 (-0,87%) A partir del 11:29AM EDT. Mercado abierto.

NexImmune, Inc.

9119 Gaither Road
Gaithersburg, MD 20877
United States
301 825 9810
https://www.neximmune.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 6

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Ms. Kristi Jones R.Ph.	CEO, President & Director	989,28k	N/A	1963
Dr. Mathias Oelke Ph.D.	Chief Scientific Officer	605,78k	N/A	1968
Mr. John Trainer M.B.A.	Consultant	1,33M	N/A	1974
Mr. Albert Nicholas Marchio II	Interim CFO & Principal Accounting Officer	N/A	N/A	1952
Mr. Karen Haslbeck	Head of Human Resources	N/A	N/A	N/A
Dr. Daniel P. Bednarik	Senior Vice President of Molecular Engineering & Protein Design	N/A	N/A	N/A
Dr. Robert Douglas Knight M.D.	Chief Medical Officer	454,77k	N/A	1951
Mr. Chad Rubin	Senior Vice President of Corporate Affairs	N/A	N/A	N/A
Dr. Jack A. Ragheb M.D., Ph.D.	Senior Vice President of Translational Science	N/A	N/A	N/A
Mr. Matthew Schiller	Head of Business Development	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Gobierno corporativo

El ISS Governance QualityScore de NexImmune, Inc., a día 1 de mayo de 2024, es 10. Las puntuaciones base son Auditoría: 9; Tablero: 8; Derechos de los accionistas: 8; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.